The combined assessment of analysts suggests that 'Revenue- Established Brands- Int'l- Non-Opioid Pain, Bone and Dermatology- Arcoxia' will likely reach $67.07 million. The estimate indicates a ...
The "Osteoarthritis - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...